Download full report with analyst certification and important disclosures
Sep 11 2020, 07:30 IST/BST
Filsuvez achieving the primary endpoint in its Phase III trial for epidermolysis bullosa (EB) now makes drug approval highly likely and opens the pathway for commercialisation. It could be the first drug ever approved for EB, for which the addressable market is very material (exceeding $1bn). Now assuming a 90% probability of drug approval and commercial launch of Filsuvez, we are increasing our price target to £4.80 - implying the share price can more than double from current levels.